The new official clarification reinforces a key principle for aesthetic medicine: injectable fillers are medical devices intended for qualified healthcare professionals, not cosmetic products for unrestricted retail sale.
The Italian Ministry of Health has issued an important clarification regarding the distribution and sale of injectable fillers intended for professional use. The circular, dated 11 May 2026 and published by the Ministry on 20 May 2026, addresses the sale of absorbable and non-absorbable substances used as injectable fillers, including distribution through pharmacies, para-pharmacies and online channels.
The clarification confirms that injectable fillers fall within the scope of Regulation (EU) 2017/745 on medical devices. As such, they may be placed on the market and used only when they comply with the applicable safety and performance requirements and when they are supplied and used according to the manufacturer’s intended purpose.
This point is essential: injectable fillers are not cosmetic products. They are professional-use medical devices intended to be used by qualified healthcare professionals. Their use requires specific medical expertise and they are not intended for self-administration.
For pharmacies, para-pharmacies, distributors and e-commerce operators, the Ministry’s position introduces a clear operational responsibility: sales channels must ensure that these products are supplied only to subjects with the necessary professional qualifications. Any sales model that makes injectable fillers directly accessible to private individuals or to people without the required professional competence may conflict with the principle of compliant use under the EU Medical Device Regulation.
This clarification also strengthens a broader public health message. Injectable treatments must be performed in appropriate professional settings, by qualified medical personnel, and within a controlled supply chain. The aim is to reduce inappropriate use, protect patients and support a safer, more transparent aesthetic medicine market.
CMed Aesthetics welcomes this regulatory clarification as an important step toward greater responsibility across the entire aesthetic medicine ecosystem. For manufacturers, distributors, clinics and healthcare professionals, compliance is not only a legal requirement. It is a fundamental condition for patient safety, professional integrity and long-term trust in the sector.
The message is clear: injectable fillers must remain within professional medical channels. Distributors and online operators must verify the qualification of purchasers, avoid unrestricted retail exposure and maintain appropriate documentation of the checks carried out.
In a market where digital commerce is increasingly relevant, this clarification confirms that online sales are not an exception. E-commerce platforms and digital distributors are subject to the same principles as physical channels: professional-use medical devices must be supplied only to qualified professionals.
For CMed Aesthetics, this reinforces a vision of aesthetic medicine based on science, responsibility, education and professional competence. The future of the sector depends not only on innovation, but also on the correct use of medical devices and the protection of patients at every stage of the treatment journey.
